Home
Live Updates
Takeda Announces Approval of Nuvaxovid® COVID-19 Vaccine for Primary and Booster Immunization in Japan - Press Release : comparemela.com
Takeda Announces Approval of Nuvaxovid® COVID-19 Vaccine for Primary and Booster Immunization in Japan - Press Release
− Nuvaxovid Intramuscular Injection, containing Matrix-MTM adjuvant, is the first recombinant protein-based COVID-19 vaccine approved for use in Japan
Related Keywords
Japan ,
Mexico ,
South Africa ,
Australia ,
United States ,
Gary Dubin ,
Plasma Alliance ,
World Health Organization ,
Innovative Medicines Initiative ,
Covid Rd Alliance ,
Exchange Commission ,
Japan Ministry Of Health ,
Takeda Pharmaceutical Company Limited ,
Japan Agency For Medical Research ,
Nuvaxovid Intramuscular Injection ,
Japan Ministry ,
Intramuscular Injection ,
Global Vaccine Business Unit ,
New Drug Application ,
Japan Agency ,
Medical Research ,
Fiscal Year ,
Rare Genetics ,
Plasma Derived Therapies ,
Annual Report ,
comparemela.com © 2020. All Rights Reserved.